Grufity logoGrufity logo

LH

241.57USD-0.20(-0.08%)Market Closed

Laboratory Corporation of America Holdings

Market Summary

USD241.57-0.20Market Closed
-0.08%

LH Alerts

LH Stock Price

RSI Chart

Valuation

Market Cap

20.3B

Price/Earnings

10.19

Price/Sales

1.29

Price/Cashflow

8.97

Price/Sales

Profitability

Operating Margin

32.56%

Return on Equity

19.14%

Return on Assets

9.76%

Fundamentals

Revenue

Revenue (TTM)

15.3B

Revenue Y/Y

-11.24%

Revenue Q/Q

-2.46%

Earnings

Earnings (TTM)

1.8B

Earnings Y/Y

-39.93%

Earnings Q/Q

-1.62%

Price Action

52 Week Range

199.73314.45
(Low)(High)

Last 7 days

0.1%

Last 30 days

7.9%

Last 90 days

7.3%

Trailing 12 Months

-16.3%

Financial Health

Current Ratio

1.9

Debt/Equity

0.6

Debt/Cashflow

0.51

Investor Care

Buy Backs (1Y)

7.42%

Diluted EPS (TTM)

18.76

Peers (Alternatives to Laboratory Corporation of America Holdin)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
64.2B
59.8B
11.79% 3.75%
9.86
1.07
3.14% -18.15%
20.3B
15.3B
7.88% -16.34%
10.19
1.29
-7.83% -36.44%
16.9B
10.3B
7.10% -0.58%
13.7
1.64
-6.81% -43.45%
MID-CAP
7.5B
2.5B
12.17% 52.76%
27.2
3.08
11.78% 142.56%
6.9B
2.1B
7.44% 10.27%
24.88
3.22
-0.11% -14.81%
6.4B
11.6B
6.57% -24.42%
7.72
0.55
0.49% -29.54%
5.5B
5.1B
7.41% 26.63%
16.63
1.03
1.10% -32.81%
4.9B
408.1M
17.54% -43.94%
-9.19
11.99
26.10% -44.06%
4.8B
19.0B
8.95% -38.83%
3.32
0.25
-2.58% 58.43%
4.1B
700.1M
-13.79% -29.26%
88.84
6.57
47.91% -53.18%
SMALL-CAP
1.1B
1.4B
13.21% -28.42%
47.05
0.81
6.94% -77.50%
732.4M
1.2B
0.48% -14.75%
19.64
0.62
11.71% 25.50%
41.6M
46.8M
3.75% -75.32%
-1.1
0.94
-3.12% -66.57%
16.0M
19.4M
12.40% 17.80%
15.73
0.86
10.55% 120.80%
9.9M
22.3M
12.49% -93.18%
-0.17
0.26
-78.33% -207.64%

Financials for Laboratory Corporation of America Holdin

Income Statement (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Revenue-2.9%15,25915,71515,85916,12116,555
Cost Of Revenue-1.2%10,46810,59910,60110,49710,400
Gross Profit-6.4%4,7905,1165,2585,6246,154
  S&GA Expenses-0.5%2,0042,0141,9861,9521,926
Net Income-11.8%1,7561,9912,0992,3772,763
Balance Sheet
(In Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Assets-2.8%19,82620,40320,72820,38520,867
  Current Assets-13.1%4,3725,0315,2305,3316,021
    Cash Equivalents-61.6%4101,0691,2341,4732,037
  Inventory7.2%468436441401411
  Net PPE0.5%2,8852,8702,8082,8152,692
  Goodwill1.3%8,2188,1148,1667,9597,907
Liabilities-2.7%9,7159,9829,98710,09110,321
  Current Liabilities-4.6%2,5222,6432,6422,7832,888
    LT Debt, Non Current-0.5%5,3345,3605,3835,4175,417
Shareholder's Equity-3.0%10,09210,40110,72110,27310,525
  Retained Earnings-0.5%10,84510,89810,94810,45710,787
  Additional Paid-In Capital-100.0%-29---
Shares Outstanding-1.5%9091969396
* denotes actual numbers (not divided by Millions)
Cashflow (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q32021Q2
Cashflow From Operations-23.2%1,7362,2612,1473,1873,206
  Share Based Compensation-16.6%152182161138107
Cashflow From Investing-12.8%-1,838.53-1,630.53-1,427.73-758.10-636.00
Cashflow From Financing-21.9%-1,266.13-1,038.80-833.07-1,058.20-1,173.20
  Dividend PaymentsInfinity%260000
  Buy Backs29.4%2,2001,7001,600669
* denotes actual numbers (not divided by Millions)

Risks

What is the probability of a big loss on LH?

51.9%


Probability that Laboratory Corporation of America Holdin stock will be more than 20% underwater in next one year

36.5%


Probability that Laboratory Corporation of America Holdin stock will be more than 30% underwater in next one year.

19.2%


Probability that Laboratory Corporation of America Holdin stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does LH drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Laboratory Corporation of America Holdin was unfortunately bought at previous high price.

Returns

Cumulative Returns on LH

11.2%


10-Year Cumulative Returns

10.0%


7-Year Cumulative Returns

9.3%


5-Year Cumulative Returns

12.7%


3-Year Cumulative Returns

What are the long-term rolling returns for LH?

FIve years rolling returns for Laboratory Corporation of America Holdin.

Which funds bought or sold LH recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2022-11-23
Toroso Investments, LLC
REDUCED
-2.17
-325,000
1,919,000
0.08%
2022-11-23
Eagle Bay Advisors LLC
UNCHANGED
-
-3,592
25,000
0.01%
2022-11-22
B. Riley Wealth Advisors, Inc.
ADDED
60.25
229,000
805,000
0.02%
2022-11-22
TEACHERS RETIREMENT SYSTEM OF THE STATE OF KENTUCKY
NEW
-
1,828,000
1,828,000
0.02%
2022-11-22
CVA Family Office, LLC
UNCHANGED
-
-1,000
8,000
-%
2022-11-22
CONTINENTAL INVESTORS SERVICES, INC.
NEW
-
214,000
214,000
0.01%
2022-11-21
Parallax Volatility Advisers, L.P.
NEW
-
179,000
179,000
-%
2022-11-21
FourThought Financial, LLC
NEW
-
1,000
1,000
-%
2022-11-21
Integrated Investment Consultants, LLC
SOLD OFF
-100
-209,000
-
-%
2022-11-21
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
REDUCED
-2.12
-5,281,000
31,235,000
0.05%

1–10 of 44

Latest Funds Activity

Are funds buying LH calls or puts?
Are funds bullish or bearish(Calls - Puts)?
No. of funds that own LH

Laboratory Corporation of America Holdin News

MarketWatch

IQVIA Holdings Inc. stock falls Friday, underperforms market.27 hours ago

LH Fair Value

Recent SEC filings of Laboratory Corporation of America Holdin

View All Filings
Date Filed Form Type Document
Nov 18, 2022
S-3ASR
S-3ASR
Nov 10, 2022
4
Insider Trading
Nov 08, 2022
4
Insider Trading
Nov 08, 2022
4
Insider Trading
Nov 03, 2022
4
Insider Trading
Nov 03, 2022
4
Insider Trading
Nov 03, 2022
4
Insider Trading
Nov 01, 2022
10-Q
Quarterly Report
Oct 31, 2022
8-K
Current Report
Oct 27, 2022
8-K
Current Report

Latest Insider Trading transactions for LH

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2022-11-08
Schroeder Mark S
SOLD
-259,660
232.67
-1,116
EVP, President-Diagnostics Lab
2022-11-07
Schroeder Mark S
SOLD FOR TAXES
-208,990
233.77
-894
EVP, President-Diagnostics Lab
2022-11-07
Caveney Brian J
SOLD FOR TAXES
-208,990
233.77
-894
EVP, President of Diagnostics
2022-11-05
Schroeder Mark S
ACQUIRED
-
-
2,010
EVP, President-Diagnostics Lab
2022-11-05
Caveney Brian J
ACQUIRED
-
-
2,010
EVP, President of Diagnostics
2022-11-01
EISENBERG GLENN A
ACQUIRED
-
-
12,032
Chief Financial Officer, EVP
2022-11-01
Schechter Adam H
SOLD FOR TAXES
-198,746
222.56
-893
President & CEO
2022-11-01
Schechter Adam H
ACQUIRED
-
-
2,007
President & CEO
2022-11-01
EISENBERG GLENN A
SOLD FOR TAXES
-1,190,250
222.56
-5,348
Chief Financial Officer, EVP
2022-11-01
Kirchgraber Paul R
SOLD FOR TAXES
-198,524
222.56
-892
CEO, Covance Drug Development

1–10 of 50

Adam H. Schechter
65535
Laboratory Corporation of America Holdings operates as an independent clinical laboratory company worldwide. It operates in two segments, Labcorp Diagnostics (Dx) and Labcorp Drug Development (DD). It offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, Pap tests, hemoglobin A1C and vitamin D products, prostate-specific antigens, tests for sexually transmitted diseases, hepatitis C tests, microbiology cultures and procedures, and alcohol and other substance-abuse tests. The company also provides specialty testing services comprising gene-based and esoteric testing; advanced tests target specific diseases, including anatomic pathology/oncology, cardiovascular disease, coagulation, diagnostic genetics, endocrinology, infectious disease, women's health, pharmacogenetics, and parentage and donor testing; and occupational testing services, medical drug monitoring services, chronic disease programs, and kidney stone prevention tests. It provides online and mobile applications to enable patients to check test results; and online applications for managed care organizations. It offers end-to-end drug development, medical device, and diagnostic development solutions from early-stage research to clinical development and commercial market access. It serves managed care organizations, biopharmaceutical companies, physicians and other healthcare providers, hospitals and health systems, governmental agencies, employers, patients and consumers, contract research organizations, crop protection and chemical companies, academic institutions, and independent clinical laboratories. The company was founded in 1971 and is headquartered in Burlington, North Carolina.

LH Income Statement

2022-09-30
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($)
$ in Millions
3 Months Ended9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Net restructuring and other special charges$ 15.1$ 6.5$ 72.1$ 35.3
Operating Income (Loss)469.4766.91,683.22,528.9
Interest Expense46.342.2131.0169.0
Equity method income, net1.78.46.520.9
Investment income4.13.27.28.3
Other, net(7.3)31.9(27.8)51.5
Earnings before income taxes421.6768.21,538.12,440.6
Provision for income taxes68.4180.4333.9614.7
Net earnings353.2587.81,204.21,825.9
Net Income (Loss) Attributable to Noncontrolling Interest0.40.51.21.6
Net Income (Loss) Attributable to Parent352.8587.31,203.01,824.3
Revenues3,606.14,062.611,202.612,064.8
Cost of Revenue2,546.42,677.17,787.37,815.5
Gross Profit1,059.71,385.53,415.34,249.3
Selling, general and administrative expenses510.0519.91,460.11,408.4
Amortization of intangibles and other assets65.292.2198.7276.7
Asset Impairment Charges0.00.01.20.0
Revenues3,606.14,062.611,202.612,064.8
Cost of Revenue2,546.42,677.17,787.37,815.5
Gross Profit1,059.71,385.53,415.34,249.3
Selling, general and administrative expenses510.0519.91,460.11,408.4
Amortization of intangibles and other assets65.292.2198.7276.7
Asset Impairment Charges0.00.01.20.0
Net restructuring and other special charges15.16.572.135.3
Operating Income (Loss)469.4766.91,683.22,528.9
Other income (expenses):    
Interest expense(46.3)(42.2)(131.0)(169.0)
Equity method income, net1.78.46.520.9
Investment income4.13.27.28.3
Other, net(7.3)31.9(27.8)51.5
Earnings before income taxes421.6768.21,538.12,440.6
Provision for income taxes68.4180.4333.9614.7
Net earnings353.2587.81,204.21,825.9
Less: Net earnings attributable to the noncontrolling interest(0.4)(0.5)(1.2)(1.6)
Net earnings attributable to Laboratory Corporation of America Holdings$ 352.8$ 587.3$ 1,203.0$ 1,824.3
Basic earnings per common share (in dollars per share)$ 3.91$ 6.10$ 13.09$ 18.79
Diluted earnings per common share (in dollars per share)$ 3.90$ 6.05$ 13.02$ 18.63

LH Balance Sheet

2022-09-30
CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)
3 Months Ended9 Months Ended
Sep. 30, 2022
USD ($)
Sep. 30, 2022
USD ($)
Dec. 31, 2021
USD ($)
Current assets:   
Cash and cash equivalents$ 409,900,000$ 409,900,000$ 1,472,700,000
Accounts Receivable, after Allowance for Credit Loss, Current2,164,200,0002,164,200,0002,261,500,000
Unbilled Contracts Receivable818,500,000818,500,000716,800,000
Supplies inventories467,700,000467,700,000401,400,000
Prepaid expenses and other511,500,000511,500,000478,100,000
Total current assets4,371,800,0004,371,800,0005,330,500,000
Property, plant and equipment, net2,884,700,0002,884,700,0002,815,400,000
Goodwill, net8,217,600,0008,217,600,0007,958,900,000
Intangible Assets, Net (Excluding Goodwill)3,807,800,0003,807,800,0003,735,500,000
Joint venture partnerships and equity method investments63,700,00063,700,00060,900,000
Deferred Income Taxes and Other Assets, Current29,400,00029,400,00021,600,000
Other assets, net451,000,000.0451,000,000.0462,600,000
Total assets19,826,000,00019,826,000,00020,385,400,000
Liabilities, Current [Abstract]   
Accounts Payable, Current765,500,000765,500,000621,300,000
Accrued Liabilities, Current1,040,800,0001,040,800,0001,404,100,000
Deferred Revenue, Current530,900,000530,900,000558,500,000
Operating Lease, Liability, Current178,100,000178,100,000187,000,000.0
Finance Lease, Liability, Current5,300,0005,300,00010,500,000
Current debt excluding finance lease liability1,700,0001,700,0001,500,000
Long-term debt, less current portion2,522,300,0002,522,300,0002,782,900,000
Long-term Debt, Excluding Current Maturities5,334,300,0005,334,300,0005,416,500,000
Commitments and contingent liabilities433,900,000433,900,000402,000,000.0
Operating Lease, Liability, Noncurrent665,900,000665,900,000642,500,000
Finance Lease, Liability, Noncurrent85,800,00085,800,00084,600,000
Deferred income taxes and other tax liabilities672,700,000672,700,000762,900,000
Noncontrolling interest9,714,900,0009,714,900,00010,091,400,000
Shareholders' equity:   
Common stock, 92.8 and 93.5 shares outstanding at March 31, 2013 and December 31, 2012, respectively18,900,00018,900,00020,600,000
Additional paid-in capital000
Retained earnings8,200,0008,200,0008,500,000
Accumulated other comprehensive income(10,845,000,000)(10,845,000,000)(10,456,800,000)
Total liabilities and shareholders' equity(761,000,000.0)(761,000,000.0)(191,900,000)
Stockholders' Equity Attributable to Parent10,092,200,00010,092,200,00010,273,400,000
Liabilities and Equity19,826,000,00019,826,000,000$ 20,385,400,000
Net earnings$ 353,200,000$ 1,204,200,000